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Abstract
Background: Suicide is an important and potentially preventable consequence of serious mental
disorders of unknown etiology. Gene expression profiling technology provides an unbiased
approach to identifying candidate genes for mental disorders. Microarray studies with post-mortem
prefrontal cortex (Brodmann's Area 46/10) tissue require larger sample sizes. This study poses the
question: to what extent are differentially expressed genes for suicide a diagnostic specific set of
genes (bipolar disorder vs. schizophrenia) vs. a shared common pathway?
Results: In a reanalysis of a large set of Affymetrix Human Genome U133A microarray data, gene
expression levels were compared between suicide completers vs. non-suicide groups within a
diagnostic group, namely Bipolar disorder (N = 45; 22 suicide completers; 23 non-suicide) or
Schizophrenia (N = 45; 10 suicide completers ; 35 non-suicide). Among bipolar samples, 13 genes
were found and among schizophrenia samples, 70 genes were found as differentially expressed.
Two genes, PLSCR4  (phospholipid scramblase 4) and EMX2  (empty spiracles homolog 2
(Drosophila)) were differentially expressed in suicide groups of both diagnostic groups by
microarray analysis. By qRT-PCR, PLSCR4 and EMX2 were significantly down-regulated in the
schizophrenia suicide completers, but could not be confirmed in bipolar disorder.
Conclusion: This molecular level analysis suggests that diagnostic specific genes predominate to
shared genes in common among suicide vs. non-suicide groups. These differentially expressed,
candidate genes are neural correlates of suicide, not necessarily causal. While suicide is a complex
endpoint with many pathways, these candidate genes provide entry points for future studies of
molecular mechanisms and genetic association studies to test causality.
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Background
Suicide is the eleventh leading cause of death for all Amer-
icans with an age-adjusted annual rate of 10.5 per
100,000 in 2003 [1]. More than 90% of suicide compl-
eters have a psychiatric disorder and mood related disor-
ders are the most common disease associated with suicide
[2,3]. Patients suffering with bipolar disorder and schizo-
phrenia have greatly increased rates of suicide with
approximately 10% of patients dying of suicide [4,5].
Bipolar disorder and schizophrenia share common risk
factors for suicide completion such as depression, previ-
ous suicide attempts, hopelessness, substance abuse, agi-
tation, and poor adherence to treatment [4,5]. Suicide is a
complex endpoint with many factors and pathways lead-
ing to death [6]. The hypothesis of a shared causation for
suicide suggests common pathways and genes may func-
tion as susceptibility factors in both disorders. Alterna-
tively, there could be specific distinct pathways within a
diagnostic group.
Microarray technology provides an unbiased approach to
the molecular causes of psychiatric disorders by examin-
ing the gene expression profile of cases vs. controls [7,8].
Recent microarray studies identified differentially
expressed genes between suicide and depression patients
vs. normal controls [9-11]. However, due to the small
magnitude of the differential gene expression, the genetic
heterogeneity of these mental disorders, and the mixed
cellular nature of the brain tissue available [12], microar-
ray studies with small sample sizes are prone to generate
many false positive results [13]. Analysis of larger data sets
pooled from independent studies increase the statistical
power to find differentially expressed genes with small
effect sizes in microarray studies. Recently, a large micro-
array data set generated by the Stanley Medical Research
Institute has become available online (SMRIDB) [14].
This database contains clinical information and microar-
ray data from 12 independent studies with post-mortem
brain tissues of depression, bipolar disorder, schizophre-
nia, and unaffected control cohorts [15]. In this study, we
reanalyzed this large microarray data set of bipolar disor-
der and schizophrenia patients. The question posed is, "to
what extent are differentially expressed genes for suicide
specific to diagnosis (bipolar disorder vs. schizophrenia)
vs. a shared common pathway?"
Results
Suicide candidate genes in bipolar disorder and 
schizophrenia
Chi square tests of association indicated no difference in
demographic variables between suicide vs. non-suicide
subgroups within bipolar disorder. In contrast, age and
smoking showed significant differences with suicide vs.
non-suicide in the schizophrenia subgroup. Also, brain
pH and sex significantly affected the expression levels of
the differentially expressed genes between suicide vs. non-
suicide groups within schizophrenia (Table 1). As shown
in Table 1, none of these variables met the two criteria for
inclusion as covariates in the two disorders (see meth-
ods). Therefore, we used no covariates in the omnibus
model to provide a generalizable, single, same model for
both schizophrenia and bipolar disorder. Between the sui-
cide vs. non-suicide groups within bipolar disorder, a
total of 13 genes were differentially expressed (Table 2).
Among these genes, 10 genes were down-regulated and 3
genes including gamma-amino butyric acid A receptor, α5
subunit (GABRA5) were up-regulated.
Between the suicide vs. non-suicide group within schizo-
phrenia, 70 genes were differentially expressed (Table 3).
Most of these genes were down-regulated. From the above
lists of differentially expressed genes, within diagnostic
Table 1: Demographic factors of the suicide group and the non-suicide group in bipolar disorder and schizophrenia
Bipolar disorder (n = 45) Schizophrenia (n = 45)
Suicide n = 22 Non-suicide n = 23 vs1 suicide vs2 expression Suicide n = 10 Non-suicide n = 35 vs1 suicide vs2 expression
Age 44.3 ± 10.9 45.4 ± 11.3 n.s n.s 34.5 ± 7.6 44.3 ± 9.1 0.003 n.s
Sex (M/F) 11/11 12/11 n.s n.s 6/4 28/7 n.s < 0.001
PMI 36.8 ± 19.3 36.8 ± 16.9 n.s n.s 35.3 ± 17.9 31.4 ± 15.0 n.s n.s
Brain pH 6.4 ± 0.3 6.4 ± 0.3 n.s < 0.0001 6.4 ± 0.3 6.4 ± 0.3 n.s 0.005
Smoking3 8/9/5 13/6/4 n.s n.s 3/2/5 25/5/5 0.03 n.s
Alcohol 4 2/7/4/2/5/2/0 4/4/2/3/5/4/1 n.s n.s 3/2/1/0/2/2 9/7/4/4/3/8 n.s n.s
Drug abuse5 7/3/4/4/1/3 9/1/2/2/2/7 n.s n.s 4/1/1/0/2/2/0 17/3/2/3/3/5/2 n.s n.s
1P-values less than 0.05 were considered significant.
2P-values listed represent the lowest. FDR P-values less than 0.05 were considered significant.
3Smoking; Yes/No/Unknown
4Alcohol; Little or none/Social/Moderate drinking in past/Moderate drinking in present/Heavy drinking in past/Heavy drinking in present.
5Drug abuse; Little or none/Social/Moderate drug use in past/Moderate drug use in present/Heavy drug use in past/Heavy drug use in present/
Unknown.
The continuous variables represent the mean ± S.D. n.s., not significant.BMC Genomics 2007, 8:413 http://www.biomedcentral.com/1471-2164/8/413
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groups, two genes overlapped (Fig. 1A). Specifically, the
phospholipid scramblase 4 (PLSCR4) and empty spiracles
homolog 2, Drosophila (EMX2) genes were down-regu-
lated in both suicide groups compared to the non-suicide
groups. As negative controls, the normalization control
probe set of 100 genes were tested by the same ANOVA
model, and no genes met our statistical criteria (Fold
Change ≥ |1.3| and FDR < 0.1) between the suicide group
vs. non-suicide group within bipolar or schizophrenia
diagnostic categories.
Real time-PCR (RT-PCR) tested the validity of these two
shared, differentially expressed genes in the available sub-
set of the microarrayed samples. In the schizophrenia sui-
cide group, the EMX2 and PLSCR4 expression levels were
significantly down-regulated by comparison of mean
expression levels (EMX2 t(9) = 2.42, p = 0.02; PLSCR4
t(18) = 3.77, p = 0.0005) in the suicide group compared
to the non-suicide group (Fig 1B). The estimated fold
changes in the suicide group were -1.51 for EMX2 and -
2.16 for PLSCR4 relative to the non-suicide group. These
differences were consistent with our microarray data.
However, in bipolar disorder, these two genes could not
be validated in a subset of tissues available from the orig-
inal microarray study patients (Fig. 1B). These results
highlight the overall findings that few common differen-
tially genes for suicide vs. non-suicide exist between diag-
nostic groups.
Biological process in the differentially expressed genes
Functional annotation of the differentially expressed
genes by Gene Ontology indicated that 9 biological proc-
esses were significantly overrepresented (at level 4; P <
0.05) among the suicide candidate genes in the schizo-
phrenia cohort (Fig. 2). The transport genes were the most
commonly over-represented biological process in our sui-
cide candidate gene list for schizophrenia, including the
glial, high affinity, glutamate transporter (SLC1A3). In
contrast, no significantly over-represented biological
process group emerged with suicide candidate genes in
the bipolar disorder group.
Additionally, we analyzed the list of differentially
expressed genes for each diagnosis by the Ingenuity Path-
ways Analysis (IPA) software to identify biological path-
ways and networks. We identified distinct signaling
networks from suicide candidate genes that included the
EMX2 gene in both disorders (Fig. 3). In bipolar disorder,
the pathway perspective suggested a signaling network
related to both cellular movement and cell to cell signal-
ing, with interactions encompassing 10 differentially
expressed, suicide candidate genes (Fig. 3A). By contrast,
in schizophrenia patients, the differentially expressed
genes were related in a cell death signaling network (Fig.
3B).
Discussion
In this re-analysis study, we explored suicide candidate
genes associated with bipolar disorder and schizophrenia
using an unbiased genome-wide expression profiling
strategy. To identify suicide specific effects on the expres-
sion level of genes, we compared a suicide completers
group to a non-suicide group within the same diagnostic
category. The most important finding of this study is the
identification of suicide candidate gene lists for bipolar
disorder and schizophrenia with only two differentially
expressed (suicide vs. non-suicide) genes in both bipolar
and schizophrenia cohorts namely PLSCR4 and EMX2 by
microarray analysis. The overlap of the two gene lists is
small, suggesting few common, shared genes. For schizo-
Table 2: Summary of differentially expressed genes between the suicide completer group vs. non-suicide group in bipolar disorder with 
fold change relative to non-suicide group.
Gene symbol Description FC1 P-value2 P/A call3
TM4SF1 transmembrane 4 L six family member 1 -1.6 0.07 P
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -1.5 0.05 P
EMX2 empty spiracles homolog 2 (Drosophila) -1.4 0.09 P
LDLR low density lipoprotein receptor -1.4 0.05 P
ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) -1.4 0.05 P
PLSCR4 phospholipid scramblase 4 -1.4 0.05 P
ZHX2 zinc fingers and homeoboxes 2 -1.4 0.07 P
MRNA; cDNA DKFZp586B211 (from clone DKFZp586B211) -1.4 0.09 P
TIMP1 TIMP metallopeptidase inhibitor 1 -1.3 0.05 A
NAV2 neuron navigator 2 -1.3 0.05 P
TRIM23 tripartite motif-containing 23 1.4 0.09 P
STCH stress 70 protein chaperone, microsome-associated, 60 kDa 1.3 0.09 P
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 1.3 0.09 P
1FC represents ratio of geometric means between suicides vs. non-suicide.
2 P-values were adjusted by FDR.
3Absent (A) or Present (P) call by MAS 5BMC Genomics 2007, 8:413 http://www.biomedcentral.com/1471-2164/8/413
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Table 3: Summary of differentially expressed genes between the suicide completer group vs. non-suicide group in schizophrenia with 
fold change relative to non-suicide group.
Gene symbol Description FC1 FDR2 P/A call3
GJA1 gap junction protein, alpha 1, 43 kDa (connexin 43) -2.0 0.02 P
MT1X metallothionein 1X -1.9 0.04 P
MT1M metallothionein 1M -1.9 0.06 P
AGXT2L1 alanine-glyoxylate aminotransferase 2-like 1 -1.9 0.03 P
SDC4 syndecan 4 (amphiglycan, ryudocan) -1.7 0.01 P
SOX9 SRY (sex determining region Y)-box 9 -1.7 0.02 P
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 -1.7 0.02 P
HSPB1 heat shock 27 kDa protein 1 -1.7 0.04 P
EIF5A eukaryotic translation initiation factor 5A -1.7 0.06 P
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 -1.6 0.04 P
ID4 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein -1.6 0.02 P
APOE apolipoprotein E -1.6 0.03 P
PLSCR4 phospholipid scramblase 4 -1.6 0.03 P
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) -1.6 0.02 P
TUBB2B tubulin, beta 2B -1.5 0.04 P
MT1E metallothionein 1E (functional) -1.5 0.03 P
FAM107A family with sequence similarity 107, member A -1.5 0.03 P
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 -1.5 0.05 P
GLUL glutamate-ammonia ligase (glutamine synthetase) -1.5 0.04 P
ALDH1L1 aldehyde dehydrogenase 1 family, member L1 -1.5 0.02 P
DDIT4 DNA-damage-inducible transcript 4 -1.5 0.04 P
MT1G metallothionein 1G -1.5 0.04 P
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 -1.5 0.08 P
PPAP2B phosphatidic acid phosphatase type 2B -1.5 0.05 P
EMX2 empty spiracles homolog 2 (Drosophila) -1.5 0.05 P
TP53BP2 tumor protein p53 binding protein, 2 -1.5 0.03 P
MT1H metallothionein 1H -1.5 0.02 P
APOLD1 apolipoprotein L domain containing 1 -1.4 0.08 P
FGFR3 fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) -1.4 0.03 P
FXYD1 FXYD domain containing ion transport regulator 1 (phospholemman) -1.4 0.00 P
NOTCH2 Notch homolog 2 (Drosophila) -1.4 0.03 P
METTL7A methyltransferase like 7A -1.4 0.05 P
SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) -1.4 0.06 P
BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 1 -1.4 0.03 P
MT1F metallothionein 1F (functional) -1.4 0.05 P
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) -1.4 0.02 P
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 -1.4 0.05 P
TPD52L1 tumor protein D52-like 1 -1.4 0.02 P
RHOBTB3 Rho-related BTB domain containing 3 -1.4 0.05 P
VIL2 villin 2 (ezrin) -1.4 0.03 P
NDRG2 NDRG family member 2 -1.4 0.06 P
CLDN10 claudin 10 -1.4 0.06 P
NTSR2 neurotensin receptor 2 -1.4 0.03 A
ITPKB inositol 1,4,5-trisphosphate 3-kinase B -1.4 0.10 P
SDC2 syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan) -1.4 0.03 P
IL17RB interleukin 17 receptor B -1.3 0.03 P
SPON1 spondin 1, extracellular matrix protein -1.3 0.02 P
LOC645745  metallothionein 1H-like protein -1.3 0.03 P
ITGB4 integrin, beta 4 -1.3 0.03 P
MLC1 megalencephalic leukoencephalopathy with subcortical cysts 1 -1.3 0.05 P
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide -1.3 0.05 P
RAB31 RAB31, member RAS oncogene family -1.3 0.05 P
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide -1.3 0.05 P
AHCYL1 S-adenosylhomocysteine hydrolase-like 1 -1.3 0.03 P
CX3CR1 chemokine (C-X3-C motif) receptor 1 2.1 0.02 P
C3  complement component 3 1.6 0.02 P
CRH corticotropin releasing hormone 1.6 0.05 P
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 1.5 0.03 PBMC Genomics 2007, 8:413 http://www.biomedcentral.com/1471-2164/8/413
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phrenia, but not bipolar disorder, the differential expres-
sion of PLSCR4 and EMX2 was confirmed by RT-PCR. The
Phospholipid scramblase (PLSCR) is an integral mem-
brane protein that catalyzes Ca2+-induced bidirectional
movement of phospholipids [16]. Four isoforms have
been cloned, and PLSCR4  was the major isoform
expressed in the brain [17]. However, the biological role
of the PLSCR4 remains unknown. While speculative, the
changes in phospholipids membrane composition might
have pleiotropic effects as evidence suggests that mem-
brane composition can change G protein coupled recep-
tors' functioning and downstream effector signalling
[18,19] as well as voltage-dependent K+ channels [20].
EMX2 is a homeodomain containing transcription factor,
which plays a crucial role in forebrain patterning and
development in mouse models [21]. This finding suggests
a possible neurodevelopmental process whereby variation
in forebrain development may be a risk factor for suicide
completion behaviour associated with schizophrenia. Of
note, these differentially expressed genes are neural corre-
lates of suicide and not necessarily causal. They could be
epiphenomenon. The questions remain of 1) how these
genes function to influence suicide and 2) what interme-
diate phenotype would be appropriate to demonstrate
their possibly causal role.
Microarray studies with small sample sizes result in low
statistical power and its attendant "noise discovery". This
analysis and post-mortem sample size with replicates is
noteworthy for an adequately powered sample to detect
1.3 fold changes, improving sensitivity, reliability, and
signal to noise issues.
Previous smaller microarray studies have suggested that
GABAA  receptor subunits and glutamate-related genes
were differentially expressed in bipolar disorder and
schizophrenia as well as in suicide completers associated
with these disorders [8,10]. We identified the up-regula-
tion of gamma-amino butyric acid A receptor, α5
(GABRA5) subunit gene in suicide associated with bipolar
disorder, confirming a previous report [10]. The expres-
sion levels of two glutamate-related genes, Glutamate-
ammonia ligase (GLUL) and glial high affinity glutamate
transporter member 3 (SLC1A3) were decreased in suicide
completers with schizophrenia. The serotonergic and
noradrenergic systems have been suggested to be associ-
ated with suicide [22]. However, no genes related to these
two neurotransmitter systems were identified, consistent
with a previous report [23]. This negative finding may sug-
gest indirect effects on these neurotransmitter systems.
Genetic linkage studies have identified several loci associ-
ated with suicidal behaviors in bipolar disorders. Signifi-
cant and suggestive linkages for suicide were mapped on
chromosome 2, 5, and 10 from 162 bipolar pedigrees
[24]. Among this study's suicide candidate genes associ-
ated with bipolar disorder, the tripartite motif-containing
23 (TRIM23) gene is located close to the significantly
linked D5S1725 marker on chromosome 5. Another large
scale genetic linkage study for bipolar disorder using 1060
individuals identified linkage on chromosome 10q25.3
for suicide attempts [25]. The microarray differentially
expressed candidate gene EMX2 is included in this region
of interest. Therefore, these two genes may be apt for
future genetic association studies for suicide associated
with bipolar disorder, proving causation.
While this reanalysis study has the strengths of a larger
sample size, independent replicates, and well character-
ized patient samples from specific areas of cortex, the find-
ing should be interpreted cautiously as this study has
some limitations. First, the mixed cellular nature of the
brain samples might lower sensitivity due to dilutional
effects as opposed to pure neuronal cells of a specific cor-
tical layer [12]. In general, most microarray studies with
post-mortem brain tissues find fold changes of less than 2
DUSP6 dual specificity phosphatase 6 1.5 0.04 P
NPY neuropeptide Y 1.4 0.03 P
SLC25A23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 1.4 0.03 A
LAPTM5 lysosomal associated multispanning membrane protein 5 1.4 0.03 P
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 1.4 0.01 P
TYROBP TYRO protein tyrosine kinase binding protein 1.4 0.03 P
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain 1.4 0.03 P
P2RY13 purinergic receptor P2Y, G-protein coupled, 13 1.3 0.02 A
CSF1R colony stimulating factor 1 receptor 1.3 0.03 P
HLA-DRA major histocompatibility complex, class II, DR alpha 1.3 0.04 A
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 1.3 0.05 P
A2M alpha-2-macroglobulin 1.3 0.03 P
1FC represents ratio of geometric means between suicides vs. non-suicide.
2 P-values were adjusted by FDR.
3Absent (A) or Present (P) detection call by MAS5 statistical algorithm
Table 3: Summary of differentially expressed genes between the suicide completer group vs. non-suicide group in schizophrenia with 
fold change relative to non-suicide group. (Continued)BMC Genomics 2007, 8:413 http://www.biomedcentral.com/1471-2164/8/413
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fold, including this study. Second, although smoking,
alcohol, and drug abuse were measured as confounding
factors, all possible unmeasured, confounding variables
for suicide cannot be formally excluded, such as severity
of illness (especially the last episode for suicide compl-
eters), personality traits, hopelessness, agitation, depres-
sive symptoms, and stress. Third, these findings are
correlational and not causal. Fourth, these gene lists
should be considered as provisional until confirmed by
replications in independent sets of biological samples.
Conclusion
By reanalyzing a large microarray dataset, a list of differen-
tially expressed candidate genes for suicide within bipolar
disorder or within schizophrenia have been identified.
The overlap of genes in common among these two gene
lists is small, with a larger number of disorder specific
genes being found. This finding suggests that disorder-
specific pathways predominate over common pathways at
the molecular level. Two novel candidate genes, PLSCR4
and EMX2, were confirmed as differentially expressed in
schizophrenia between suicide completers vs. non-suicide
groups.
Methods
Microarray data and Patient Samples
The brain tissues were meticulously collected in a stand-
ardized manner via pathologists in the offices of the Med-
ical Examiner in several states with the families'
permission under the aegis of the Stanley Foundation
Brain Collection (Array Collection plus Consortium Col-
lection) [26]. The selection of specimens, clinical infor-
mation, diagnoses of patients, and processing of tissues
were conducted by Stanley Foundation Consortium as
described previously [26]. Gene expression profiling uti-
lized post-mortem prefrontal cortex (Brodmann's Area
46/10) mRNA and Affymetrix Human Genome U133 Set
A (HGU133A) using standardized techniques as
described [26,27]. The prefrontal cortex was selected as
the region of interest due to its role in executive function-
ing, impulsivity ("lack of premeditation"), and decision
making. Disadvantageous decision making and impulsiv-
ity have been found to increase the risk of suicide [28,29].
Distribution of gene ontology groups for biological process  at level 4 of differentially expressed genes between suicide vs.  non-suicide in schizophrenia cohorts Figure 2
Distribution of gene ontology groups for biological process at 
level 4 of differentially expressed genes between suicide vs. non-
suicide in schizophrenia cohorts.
Differentially expressed genes between suicide completer vs Figure 1
Differentially expressed genes between suicide completer 
vs. non-suicide group in bipolar disorder and schizophre-
nia cohorts. (A) Venn diagram of differentially expressed genes 
between suicide completer vs. non-suicide groups within bipolar 
and schizophrenia. (B) Mean expression levels of PLSCR4 (phos-
pholipid scramblase 4) and EMX2 (empty spiracles homolog 2 
(Drosophila)) mRNA transcripts were determined for suicide 
completers vs. non-suicide groups within both bipolar disorder 
and schizophrenia in prefrontal cortex by qRT-PCR. The bars rep-
resent mean ± SEM. In schizophrenia, the mean expression levels 
of both genes were significantly down-regulated in the suicide 
group (n = 5) relative to the non-suicide cases (n = 25) by one-
tailed, t-tests for unequal variances (EMX2 t(9) = 2.42, p = 0.02; 
PLSCR4 t(18) = 3.77, p = 0.0005). The estimated fold changes in 
the suicide group were -1.51 for EMX2 and -2.16 for PLSCR4 rela-
tive to the non-suicide group, consistent with our microarray 
data. In the bipolar disorder samples, no significant differences in 
mean expression levels for either gene were found between the 
suicide (n = 14 for EMX2; n = 12 for PLSCR4) vs. non-suicide cases 
(n = 15 for EMX2 ; n = 11 for PLSCR4) by unequal variance t-tests. 
* p < .05 ; *** p < .001.BMC Genomics 2007, 8:413 http://www.biomedcentral.com/1471-2164/8/413
Page 7 of 10
(page number not for citation purposes)
The Stanley Foundation's microarray database is an anon-
ymous, de-identified dataset without any protected health
information. Patients' demographic variables used in this
study are listed in Table 1.
The robust multi-array averages (RMA)-normalized
microarray data from four independent studies were
downloaded from the SMRIDB. Microarray data from the
same platform, Affymetrix Human Genome U133 Set A
(HGU133A), were used to avoid platform-to-platform
variation. The platform contains 22,215 probe sets. Qual-
ity control analyses for each chip were described previ-
ously [15]
For the bipolar disorder cohort, the total dataset consisted
of 49 suicide completers' gene chips and 58 non-suicide
gene chips, while for schizophrenia cohort, the total data-
set consisted of 22 suicide completer gene chips and 89
non-suicide chips. Among 45 bipolar samples, there were
22 suicide cases, and 23 non-suicide cases. Among 45
schizophrenia patients, there were 10 suicide cases, and
35 non-suicide cases. Two to three microarray chip data-
sets were generated from the each patient's sample. These
repeated microarray data from each patient were treated
as technical replicates.
Statistical analysis of microarray data
Microarray data was analyzed by a statistical method
described previously with slight modifications [26].
Briefly the following steps were followed within each
diagnostic group (see Table 1). First, the differentially
expressed genes between suicide completers vs. non-sui-
cide groups were filtered by average fold change (FC ≥
|1.3|) using the BRB-array tool[30] without covariates.
Second, the influence of continuous demographic varia-
bles (such as age, post-mortem interval (PMI) and brain
pH) with the nominal variable suicide was tested using
ANOVA. Then, categorical variables such as sex, smoking,
alcohol and drug abuse were tested using chi square tests
of association (Statview software SAS, Cary, NC). In addi-
tion, correlation analyses of the demographic factors with
expression levels of the differentially expressed probe sets
from step 1 were performed. Continuous variables were
analyzed by Spearman's rank correlation and categorical
variables were tested by ANOVA. P-values were adjusted
by False Discovery Rate (FDR) in both tests [31]. Third,
significant confounding factors were tested as possible
Ingenuity pathway analysis of EMX2 and differentially expressed suicide candidate genes in bipolar disorder (A) and schizophre- nia (B) Figure 3
Ingenuity pathway analysis of EMX2 and differentially expressed suicide candidate genes in bipolar disorder (A) and schizophrenia (B).
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covariates for ANCOVA model inclusion with the follow-
ing criteria: The variable was required to show both 1) sig-
nificant association with suicide as well as 2) significant
correlation with expression levels of the differentially
expressed genes. However, no variables met the criteria in
both disorder groups. Therefore, no covariates were used
in the omnibus ANOVA, using the factor as suicide vs.
non-suicide. As an exploratory analysis, a more liberal
FDR P-value (< 0.1) of significance was selected for
expression level differences as previously described
[32,33], using the BRB array software tool's FDR default
setting. For negative controls, we performed statistical
analysis with the HGU133A normalization control probe
sets using the same ANCOVA models, ensuring the adjust-
ment did not produce "noise" or aberrant false positives.
The Microarray Suite, version 5.0 (MAS5) software was
used to filter genes with low expression levels as either
present or absent, applying the detection call statistical
algorithm. This algorithm suggests whether a gene is
present or absent.
A power analysis estimated the sample sizes for detection
of a 1.3 fold change in a gene with a significance criterion
of P-value = 0.001 and a power of 0.90 using a previously
described method [13]. This analysis estimated a mini-
mum sample size of 27 cases per group for comparing sui-
cide completers vs. non-suicide groups within bipolar
disorder and 21 samples per group for comparing suicide
completers vs. non-suicide completers within schizophre-
nia.
Real-time quantitative PCR
Total RNA from the dorsolateral prefrontal cortex (Brod-
mann area 46) of the Array Collection was used for this
experiment. Complementary DNA was synthesized from
DNA-free RNA with a random hexamer primer and Super-
script III First-Strand Synthesis System according to the
manufacturer's protocol (Invitrogen). Using a 384-well
format with the Prism7900HT real-time detector (ABI), 2
μl aliquots of (10×) QuantiTect Primer Assay (validated
primers to the specific gene of interest; Qiagen), 10 μl (2×)
QuantiTect SYBR PCR Master mix (Qiagen), and 8 μl
cDNA were mixed together for 20 μl total reaction volume
and pipetted into single wells of the 384 PCR plate.
Amplification conditions were: (1) 1 cycle for 2 min at
50°C, (2) 1 cycle for 15 min at 95°C, and (3) 45 cycles for
15 s at 94°C, 30 s at 60°C and 30 s at 72°C and fluores-
cence was measured during the 72°C step for each cycle as
recommended by the manufacturer. The β-2 microglobu-
lin (B2M) was chosen as an endogenous control for the
normalization of target genes as it was consistently
expressed in microarray samples. A total of 32 samples per
each disorder were used for this experiment and run in
duplicate. In the bipolar disorder cohort, there were 14
suicides and 18 non-suicide cases. In schizophrenia
cohort, there were 5 suicides and 27 non-suicide cases.
These samples were matched by age, race, gender, PMI,
brain pH, side of the brain and quality of RNA. Reactions
were quantified by the comparative Ct method using
SDS2.2 software (ABI). This RT-PCR data was also statisti-
cally analyzed by the amplification plot method using the
Data Analysis for Real Time PCR (DART-PCR) approach
[34]. This method identified outliers in amplification effi-
ciency by ANOVA and calculated mean expression levels.
Statistical differences in expression levels between groups,
namely suicide completers vs. non-suicides within a diag-
nostic group, were tested by one-tail, t-test with unequal
variances (Microsoft Excel) as described [35,36]. To esti-
mate average fold changes between groups, the mean
expression values from the DART-PCR approach were
used. The alternative 2(-Delta Delta Ct) method [37] for
estimating fold change (using all the data without exclu-
sions) verified this fold change estimate. As both methods
gave similar estimates, only the DART-PCR approach esti-
mates from mean expression levels were reported.
Functional annotation
The differentially expressed genes were functionally anno-
tated using the DAVID integrated database query tool[38]
and by the over-representational analysis method [39].
Functional annotations were based on biological process
of Gene Ontology (GO) Consortium[40] at level 4. P-val-
ues less than 0.05 were considered significant.
Pathway Analysis
Biologically relevant networks were drawn from the lists
of genes that were differentially expressed in bipolar dis-
order and schizophrenia. This data was generated through
the use of Ingenuity Pathways Analysis (IPA) [41], a web-
delivered application that enables the visualization and
analysis of biologically relevant networks to discover, vis-
ualize, and explore relevant networks. Expression data sets
containing gene identifiers (Affymetrix probe set ID) and
their corresponding expression values as fold changes
were uploaded as a tab-delimited text file. Each gene iden-
tifier was mapped to its corresponding gene object in the
Ingenuity Pathways Knowledge Base. These genes, called
Focus Genes, were then used as the starting point for gen-
erating biological networks. To start building networks,
the application program queries the Ingenuity Pathways
Knowledge Base for interactions between Focus Genes
and all other gene objects stored in the knowledge base,
and generates a set of networks. The program then com-
putes a score for each network according to the fit of the
network to the set of focus genes. The score indicates the
likelihood of the Focus Genes in a given network being
found together due to random chance. A score of greater
than 2 indicates that there is a less than 1 in 100 chance
that the Focus Genes were assembled randomly into a net-
work due to random chance. The scores of the networksBMC Genomics 2007, 8:413 http://www.biomedcentral.com/1471-2164/8/413
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generated from the lists of differentially expressed genes
were 24 for Bipolar disorder (Fig 3A) and 40 for Schizo-
phrenia (Fig 3B).
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